TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Income Statement
NYSE:TEVA - New York Stock Exchange, Inc. - US8816242098 - ADR - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.62B | 16.54B | 15.85B | 14.93B | 15.88B | |||
| Minority Interest Expense | 34.00M | 320.00M | 56.00M | 53.00M | -39.00M | |||
| Cost Of Goods | 8.23B | 8.25B | 7.87B | 7.49B | 8.01B | |||
| Gross Profit | 8.39B | 8.29B | 7.98B | 7.44B | 7.86B | |||
| Operating Expenses | 4.70B | 4.70B | 4.44B | 4.25B | 4.45B | |||
| Research and Development | 1.00B | 998.00M | 953.00M | 838.00M | 967.00M | |||
| Selling, General, and Administrative Expenses | 3.73B | 3.70B | 3.50B | 3.44B | 3.40B | |||
| Operating Income | 3.69B | 3.59B | 3.54B | 3.19B | 3.42B | |||
| Interest Income/Expense | -981.00M | -933.00M | -991.00M | -904.00M | -988.00M | |||
| Other Income/Expense | 24.00M | -48.00M | -66.00M | -62.00M | -70.00M | |||
| Non Recurring Items | -3.25B | -3.89B | -3.11B | -5.38B | -1.70B | |||
| Income Before Taxes | -523.00M | -1.28B | -624.00M | -3.16B | 658.00M | |||
| Income Tax | 801.00M | 676.00M | -7.00M | -643.00M | 211.00M | |||
| Net Income | -1.29B | -1.64B | -559.00M | -2.45B | 417.00M | |||
| EBITDA | 4.72B | 4.65B | 4.69B | 4.49B | 4.75B | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.13 | -1.44 | -0.50 | -2.19 | 0.37 | |||
| Non GAAP EPS | 2.51 | 2.47 | 2.54 | 2.51 | 2.56 | |||
| Statistics | ||||||||
| Gross Profit Margin | 50.49% | 50.12% | 50.33% | 49.84% | 49.53% | |||
| Profit Margin | -7.74% | -9.91% | -3.53% | -16.39% | 2.63% | |||
| Operating Profit Margin | 22.19% | 21.69% | 22.34% | 21.34% | 21.53% | |||
All data in USD